Table 6.
Summarized clinical trials of ICIs combinations with other treatments in cancers
| Combination | NCT Number | Phase | Conditions | Regime | mOS (m) | mPFS (m) | ORR (%) |
|---|---|---|---|---|---|---|---|
| PD-1+cell therapy | NCT02843204 | I/II | Malignant Solid Tumour | Pembrolizumab+allogeneic NK cells vs. pembrolizumab | 15.5 vs. 13.3 | 6.5 vs. 4.3 | 36.4 vs. 18.5 |
| PD-1+chemotherapy | NCT03189719 | III | advanced esophageal cancer and Siewert type 1 gastro-esophageal junction cancer | pembrolizumab+chemotherapy(5-fluorouracil and cisplatin) vs. PLACEBO+chemotherapy | 12.4 vs. 9.8 | 6.3 vs. 5.8 | 45 vs. 29.3 |
| PD-1+small molecular inhibitor | NCT02133742 | IB | Renal Cell Carcinoma | Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg | NA | 20.9[1] | NA |
| CTLA-4+monoclonal antibody | NCT03241173 | I/II | Advanced malignancies | INCAGN01949 350 mg + Ipilimumab 1 mg/kg | NA | 4.6 | 0 |
| PD-1+small molecular inhibitor*2 | NCT02130466 | I/II | Melanoma/Solid Tumors | Pembrolizumab+Dabrafenib+Trametinib vs. Placebo+Dabrafenib+Trametinib | 46.3[2] vs. 26.3 | 17.0 vs. 9.9 | NA |
| PD-1 + mRNA vaccine | NCT02529072 | I | Malignant Glioma/Astrocytoma/Glioblastoma | nivolumab vs. nivolumab+DC vaccine | 8 vs. 15.3[2] | 4.3 vs. 6.3 | NA |
| PD-1+Oncolytic Virus + CTLA-4 | NCT03206073 | I/II | Colorectal Cancer et al. | 1/Arm A1 Pexa-Vec 3 x 10E^8 Plaque-forming Unit (Pfu) + Durvalumab 1500 mg vs. 2/Arm A2 Pexa-Vec 1 x 10E^9 Pfu +Durvalumab 1500 mg vs. 3/Arm B1 Pexa-Vec 3 x 10E^8 Pfu + Durvalumab 1500 mg +Tremelimumab 300 mg vs. 4/Arm B2 Pexa-Vec 1 x 10E^9 Pfu + Durvalumab 1500 mg +Tremelimumab 300 mg | 3 vs. 2.3 vs. 2.25 vs. 1.65 | 0 vs. 8.3 vs. 0 vs. 7.1 | NA |
| PD-1 + | NCT03765190 | I/II | Neoplasm Metastasis | proton radiation therapy+PD-1 antibody | NA | NA | NA |
| PD-1+Photodynamic Therapy | NCT05386056 | II | Esophageal Squamous Cell Carcinoma | Pembrolizumab+Photodynamic Therapy | NA | NA | NA |
[1] Upper limit of 95% CI was not reached since a large proportion of participants in the analysis set had their PFS data censored and there were insufficient number of participants with events to calculate the full 95% CI
[2] The upper limit is not estimable due an insufficient number of patients and events. TKI Tyrosine kinase inhibitors. Data obtained fromclinicaltrial.gov (Accessed on 24th March 2024)